A Danish Randomized Trial Comparing Breast-Preserving Therapy with Mastectomy in Mammary Carcinoma: Preliminary results

Authors

  • M. Blichert-Toft From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit
  • H. Brincker From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit
  • J. A. Andersen From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit
  • K. W. Andersen From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit
  • C. K. Axelsson From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit
  • H. T. Mouridsen From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit
  • P. Dombernowsky From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit
  • M. Overgaard From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit
  • C. Gadeberg From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit
  • G. Knudsen From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit
  • S. Borgeskov From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit
  • S. Bertelsen From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit
  • J. B. Knudsen From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit
  • J. B. Hansen From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit
  • P. E. Poulsen From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit
  • H. Willumsen From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit
  • P. Schousen From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit
  • D. Froberg From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Uni
  • J. Ørnsholt From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit
  • M. Andersen From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit
  • S. Olesen From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit
  • S. Skovgaard From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit
  • M. Øster From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit
  • H. Schumacher From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit
  • E. K. Lynderup From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit
  • C. N. Holm From the Surgical Departments of Odense, Vejle, Finsen, Herlev, Aarhus Municipal, Aalborg, Bispebjerg, Frederiksberg, Glostrup, Hillerød, Hørsholm, Frederikssund, Horsens, Kolding, Randers, Viborg, Give, Skive, and Silkeborg Hospitals, the Departments of Oncology and Radiotherapy at Odense University Hospital, Finsen Institute, Herlev Hospital, Aarhus Municipal Hospital, Vejle Hospital, Aalborg Hospital, Southern Division, the Institute of Pathology at Odense University Hospital, and the Danish Breast Cancer Cooperative Group (Dbcg), Statistical Unit

DOI:

https://doi.org/10.3109/02841868809091767

Keywords:

Breast cancer, breast-preserving therapy, mastec- tomy, multicentre trial, randomized trial, recurrence-free surviv- al

Abstract

The present study comprises 847 women operated upon for invasive breast carcinoma at 19 surgical departments and enrolled in protocol DBCG-82TM from January 1983 to November 1987. Among them 662 (78%) were allocated for breast-preserving therapy or mastectomy by randomization, while 185 patients (22%) did not accept randomization. Within the randomized group 6% could not be entered into adjuvant protocols, i.e. subsequent programmes of postoperative therapy and follow-up. This left 619 evaluable patients. In the non-randomized series 26% did not fulfil the demands for entrance into the adjuvant protocols, leaving 136 evaluable patients, 60 of whom had chosen a breast-preserving operation and 76 mastectomy. In the randomized series the patients in the two treatment arms were comparable in age, menopausal status, site of tumour, pathoanatomical diameter of the tumour, number of removed axillary lymph nodes, number of metastatic axillary lymph nodes, and distribution on adjuvant regimens. Ninety per cent of the patients in the randomized group accepted the method offered, whereas 10% declined and wanted the alternate form of operation. The median follow-up period was approximately 1.75 years. The cumulative recurrence rate in the randomized group was 13% and in the non-randomized group 7%. These results are preliminary. Life-table analyses have not so far demonstrated differences in recurrence-free survival either in the randomized or the non-randomized series.

Downloads

Download data is not yet available.

Downloads

Published

1988-01-01

How to Cite

Blichert-Toft, M., Brincker, H., Andersen, J. A., Andersen, K. W., Axelsson, C. K., Mouridsen, H. T., … Holm, C. N. (1988). A Danish Randomized Trial Comparing Breast-Preserving Therapy with Mastectomy in Mammary Carcinoma: Preliminary results. Acta Oncologica, 27(6), 671–677. https://doi.org/10.3109/02841868809091767

Issue

Vol. 27 No. 6 (1988): Acta Oncologica

Section

Articles